Funds and ETFs Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Real-time Estimate Cboe Europe 08:50:22 2024-05-01 am EDT 5-day change 1st Jan Change
1,923 GBX -0.05% Intraday chart for Hikma Pharmaceuticals PLC +5.61% +7.38%

ETFs positioned on Hikma Pharmaceuticals PLC

Name Weight AuM 1st Jan change Investor Rating
0.44% 1,120 M€ -0.11%
0.25% 3 M€ +9.95% -
0.20% 11 M€ +0.83% -
0.16% 18 M€ +2.87% -
0.15% 5 M€ +10.09% -
0.15% 14 M€ +5.66% -
0.04% 6 M€ -.--%
0.02% 10 M€ -3.35% -
0.01% 31 M€ +2.75% -
0.01% 284 M€ -.--%
0.01% 206 M€ -.--%
0.01% 1,166 M€ +0.26% -
0.01% 607 M€ +0.05% -
0.01% 23 M€ -.--% -
0.01% 786 M€ -.--%
0.01% 273 M€ +15.93%
0.00% 389 M€ +6.58% -
0.00% 34 M€ +1.51% -
0.00% 7 M€ +0.11% -
0.00% 34 M€ +6.29% -
0.00% 237 M€ +1.29% -
0.00% 302 M€ +3.73% -
0.00% 39 M€ +4.22% -
0.00% 26 M€ -4.26% -
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
24.1 USD
Average target price
28.63 USD
Spread / Average Target
+18.83%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HIK Stock
  4. Funds and ETFs Hikma Pharmaceuticals PLC